MYRIAD GENETICS INC

In Vitro & In Vivo Diagnostic Substances

MYGN Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0000899923 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$327.12M
95,649,645 shares Covers every share class this company has on file.
Insiders on file
9
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$14.00M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
4.28%
insider-held value divided by market capitalisation

What MYRIAD GENETICS INC reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$824.50M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$366.00M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
2,700
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at MYRIAD GENETICS INC

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against MYRIAD GENETICS INC.
Insider Reported role Shares Value Last action
Officers 4
Mark Verratti Mark Verratti COO 630,715 $2.01M F Shares withheld for taxes Apr 14, 2026 position reported
Brian J Donnelly Brian J Donnelly Other Executive 624,338 $1.99M A Grant or award Jun 11, 2026 position reported
Dale Muzzey Dale Muzzey Other Executive 327,256 $1.04M F Shares withheld for taxes Apr 14, 2026 position reported
Jennifer Lynne Fox General Counsel 310,362 $990.1K F Shares withheld for taxes Sep 3, 2026 position reported
Officers who also sit on the board 3
Samraat S Raha CEO 1,064,541 $3.40M A Grant or award Jun 11, 2026 position reported
Paul J. Diaz CEO 891,844 $2.84M F Shares withheld for taxes Mar 24, 2025 position reported
Daniel Skovronsky President 135,806 $433.2K A Grant or award Jun 4, 2026 position reported
Directors 2
S. Louise Phanstiel S. Louise Phanstiel Board Member 315,070 $1.01M A Grant or award Jun 4, 2026 position reported
Paul Bisaro Paul Bisaro Board Member 89,941 $286.9K A Grant or award Jun 4, 2026 position reported

Recent insider transactions

Of the 93 rows we hold, 5 are open-market purchases (P) and 6 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for MYRIAD GENETICS INC, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 3, 2026 Jennifer Lynne Fox F Shares withheld for taxes 4,398 $3.23 $14.2K SEC filing ↗
Jun 11, 2026 Brian J Donnelly A Grant or award 5,000 $3.94 $19.7K SEC filing ↗
Jun 11, 2026 Samraat S Raha A Grant or award 3,542 $3.94 $14.0K SEC filing ↗
Jun 4, 2026 Daniel Skovronsky A Grant or award 59,701 $0.00 $0 SEC filing ↗
Jun 4, 2026 S. Louise Phanstiel A Grant or award 59,701 $0.00 $0 SEC filing ↗
Jun 4, 2026 Paul Bisaro A Grant or award 59,701 $0.00 $0 SEC filing ↗
May 14, 2026 Paul Bisaro P Open-market purchase 7,500 $3.69 $27.7K SEC filing ↗
May 1, 2026 Brian J Donnelly F Shares withheld for taxes 55,975 $4.80 $268.7K SEC filing ↗
Apr 14, 2026 Dale Muzzey F Shares withheld for taxes 946 $4.91 $4.6K SEC filing ↗
Apr 14, 2026 Mark Verratti F Shares withheld for taxes 1,069 $4.91 $5.2K SEC filing ↗
Mar 22, 2026 Dale Muzzey F Shares withheld for taxes 2,019 $4.58 $9.2K SEC filing ↗
Mar 22, 2026 Mark Verratti F Shares withheld for taxes 2,055 $4.58 $9.4K SEC filing ↗
Mar 15, 2026 Dale Muzzey F Shares withheld for taxes 11,949 $4.66 $55.7K SEC filing ↗
Mar 15, 2026 Dale Muzzey F Shares withheld for taxes 4,783 $4.66 $22.3K SEC filing ↗
Mar 15, 2026 Mark Verratti F Shares withheld for taxes 5,611 $4.66 $26.1K SEC filing ↗
Mar 15, 2026 Mark Verratti F Shares withheld for taxes 9,096 $4.66 $42.4K SEC filing ↗
Mar 14, 2026 Dale Muzzey F Shares withheld for taxes 8,288 $4.66 $38.6K SEC filing ↗
Mar 14, 2026 Mark Verratti F Shares withheld for taxes 5,418 $4.66 $25.2K SEC filing ↗
Mar 14, 2026 Samraat S Raha F Shares withheld for taxes 10,816 $4.66 $50.4K SEC filing ↗
Mar 13, 2026 Dale Muzzey F Shares withheld for taxes 12,779 $4.66 $59.6K SEC filing ↗
Mar 13, 2026 Jennifer Lynne Fox F Shares withheld for taxes 5,995 $4.66 $27.9K SEC filing ↗
Mar 13, 2026 Mark Verratti F Shares withheld for taxes 9,164 $4.66 $42.7K SEC filing ↗
Mar 13, 2026 Samraat S Raha F Shares withheld for taxes 36,304 $4.66 $169.2K SEC filing ↗
Mar 12, 2026 Brian J Donnelly A Grant or award 226,804 $0.00 $0 SEC filing ↗
Mar 12, 2026 Dale Muzzey A Grant or award 173,196 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Subsidiaries — 8 legal entities

Subsidiaries of MYRIAD GENETICS INC

8 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries MYRIAD GENETICS INC names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Assurex Health, Inc. 1 Delaware
Gateway Genomics, LLC 1 Delaware
Myriad Genetic Laboratories, Inc. 1 Delaware
Myriad Genetics B.V. 1 Netherlands
Myriad Genetics GK 1 Japan
Myriad Genetics GmbH 1 Switzerland
Myriad GmbH 1 Germany
Myriad Women’s Health, Inc 1 Delaware
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from MYRIAD GENETICS INC’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from MYRIAD GENETICS INC’s own SEC filings multiplied by the closing price we hold for the same stock.

Logo: Myriad Genetics / Public domain , via Wikimedia Commons ↗ — used here to identify the company. Trademarks remain the property of their owner.